AnaptysBio, Inc.
10770 Wateridge Circle
Suite 210
San Diego
California
92121
United States
Tel: 858-362-6295
Fax: 858-362-6296
Website: http://www.anaptysbio.com/
Email: info@anaptysbio.com
About AnaptysBio, Inc.
AnaptysBio is a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics. We are developing immune cell modulators, including two checkpoint agonists in clinical-stage development, for autoimmune and inflammatory disease: rosnilimab, our anti-PD-1 agonist program in Phase 2 for the treatment of moderate-to-severe alopecia areata; and ANB032, our anti-BTLA agonist program. AnaptysBio is also developing imsidolimab, our anti-IL-36R antibody in Phase 3 for the treatment of generalized pustular psoriasis, or GPP. We also have additional preclinical programs and discovery research of potentially innovative immunology therapeutics, including ANB033, an anti-CD122 antagonist antibody for the treatment of inflammatory diseases. AnaptysBio has also developed multiple therapeutic antibodies in an immuno-oncology collaboration with GSK, including an anti-PD-1 antagonist antibody (JEMPERLI (dostarlimab-gxly)), an anti-TIM-3 antagonist antibody (cobolimab, GSK4069889) and an anti-LAG-3 antagonist antibody (GSK4074386).
124 articles with AnaptysBio, Inc.
-
Shares of AnaptysBio were climbing this morning after the company released positive interim data for its experimental peanut allergy treatment. The San Diego-based company said 13 patients or 46 percent of those in its ongoing Phase IIa trial saw increased tolerance to peanuts to 500 mg.
-
4 Biotechs Ready to Kill the Market in 2018
12/29/2017
A look at a few biotechs which should outperform the market in 2018. -
Top 5 Biotech Stocks to Buy for 2018
12/21/2017
A new RBC report is reasonably positive on the biotech sector for 2018 and here are some reasons why. -
The 2017 Biotech IPO Winners and Losers
12/21/2017
Although it was an average year for mergers and acquisitions in the biopharma industry, it was a stronger year for IPOs. -
Barring a huge meltdown, the S&P 500 will once again have a double-digit year of gains, and most investors should be looking at their 401(k)s and other accounts with some added holiday cheer.
-
AnaptysBio Reports Positive ANB019 Top-line Phase I Clinical Trial Results
11/7/2017
Top-line data demonstrated favorable safety, pharmacokinetics and pharmacodynamic properties that support advancement of ANB019 into patient Phase 2 studies.
-
AnaptysBio Announces Third Quarter 2017 Financial Results and Provides Pipeline Updates
11/7/2017
Cash, cash equivalents and investments totaled $116.7 million as of September 30, 2017, which includes net proceeds of $80.2 million from the company’s initial public offering completed in January 2017, compared to $51.2 million as of December 31, 2016.
-
AnaptysBio Announces Pricing Of Public Offering
10/13/2017
-
AnaptysBio Files Registration Statement For Proposed Public Offering
10/11/2017
-
AnaptysBio Reports Positive Topline Proof-Of-Concept Data From Phase IIa Clinical Trial Of ANB020 In Atopic Dermatitis
10/10/2017
-
AnaptysBio Announces Appointment Of J. Anthony Ware, M.D. To Board Of Directors
8/24/2017
-
AnaptysBio Announces Second Quarter 2017 Financial Results And Provides Pipeline Updates
8/11/2017
-
AnaptysBio Announces First Quarter 2017 Financial Results And Provides Pipeline Update
5/12/2017
-
AnaptysBio Release: SoCal Biotech Goes Public, Raises $75 Million
1/26/2017
-
AnaptysBio Release: Biotech Announces The Appointment Of Dominic Piscitelli As Chief Financial Officer
1/11/2017
-
AnaptysBio Announces Clearance Of U.S. IND And U.K. CTA For ANB020
12/13/2016
-
AnaptysBio Reports ANB020 Top-Line Phase 1 Clinical Trial Results
10/3/2016
-
AnaptysBio Announces Checkpoint Receptor Agonist Antibody Portfolio
9/26/2016
-
AnaptysBio Initiates Multiple Ascending Dose Cohorts In ANB020 Phase 1 Clinical Trial
7/6/2016
-
AnaptysBio Appoints Dr. Matthew Moyle As Chief Scientific Officer
4/18/2016